Which patients with localized esophageal adenocarcinoma, if any, would you offer nivolumab after lack of pCR to neoadjuvant FLOT?
Answer from: Medical Oncologist at Academic Institution
I have not been in such a situation, yet, but I am sure will be soon! My thought will be to start off with patients with a PDL1 score of at least 5. Not sure the degree of path response can predict immune therapy sensitivity, so at this time, I would treat all except the pCR but may also consider li...
Comments
Medical Oncologist at Onc San Antonio Isn’t it going to be off label at this time?
Isn’t it going to be off label at this time?